PMN — ProMIS Neurosciences Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1374339 ·
Last close
$3.21
Market Cap
$28.88M
52W High
$27.40
52W Low
$2.78
ADV30
296,385
Next earnings
2026-11-12
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -12,266,399 -11,729,656 56,693,933 53,429,280 7,294,999
Mar 2026 0 — -8,644,895 -8,244,372 67,411,571 63,814,345 6,693,999
Dec 2025 0 — -10,772,119 -10,674,088 9,182,421 6,116,556 10,441,013
Sep 2025 0 — -11,750,432 -11,580,126 21,458,147 15,399,165 12,270,792

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-42,106,116
Investing CF
—
Financing CF
$91,025,979
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.80
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-150,380,249
Inventory
—
Receivables
$215,226
ST Investments
$33,753
EBIT TTM
$-43,165,508
Pretax Income TTM
$-42,228,242
Interest Exp TTM
$0
Analysts
6

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -40,167,308 -39,719,147 9,182,421 10,441,013 -1,258,592 -28,118,579
Dec 2024 0 -16,827,478 2,778,873 18,911,456 2,423,280 16,488,176 -27,182,095
Dec 2023 0 -14,262,733 -13,212,482 13,619,145 9,865,849 3,753,296 -10,843,676
Dec 2022 0 -23,379,912 -18,062,263 6,924,646 8,272,418 -1,347,772 -17,033,883
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-42,228,243
OpCashFlow TTM
—
Assets (Latest)
$56,693,933
Forward EPS
$-4.04

Peers — same industry

TickerNameMarket CapLastDaily %
RDPTF Radiopharm Theranostics Ltd $28.89M $0.01 —
AYTU AYTU BIOPHARMA, INC $28.91M $2.66 —
SCYX SCYNEXIS INC $28.37M $2.85 —
PYRGF PyroGenesis Canada Inc. $28.34M $0.13 —
PRRUF IMMUTEP Ltd $29.47M $0.02 —

News headlines (Yahoo Finance, 1h cache)

ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
2026-11-17 07:30 · Yahoo
ProMIS Neurosciences, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
2026-11-12 21:05 · Yahoo
ProMIS Neurosciences to Participate in Upcoming Conferences in November
2026-11-05 12:00 · Yahoo
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
2026-11-03 12:00 · Yahoo
Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade
2026-10-29 12:55 · Yahoo
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
2026-09-01 12:00 · Yahoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ...
2026-08-14 05:02 · Yahoo
Promis Neurosciences Q2 Earnings Call Highlights
2026-08-14 02:04 · Yahoo
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
2026-08-13 20:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.